CCL22 and CCL17 cancer biomarkers
US10241118B2 · kind B2 · utility
0Cited by
0References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 9, 2014 |
| Grant date | Mar 26, 2019 |
| Priority date | — |
| Expiry date | Apr 9, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/7028
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides methods of obtaining information relevant to monitoring and diagnosing cancer, particularly monitoring the progression or development of cancer, monitoring the response of cancer to treatment, diagnosing cancer, making a cancer prognosis, predicting the likelihood of a cancer responding to treatment and stratifying subjects having cancer. The methods involve determining the ratio of circulating CCL17 to circulating CCL22 in a sample from a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.